Publications by the researcher in collaboration with Norma C. Gutiérrez (11)

2013

  1. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Leukemia, Vol. 27, Núm. 10, pp. 2056-2061

  2. Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control (Leukemia (2013) 27 (2112))

    Leukemia

2012

  1. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Blood, Vol. 119, Núm. 3, pp. 687-691

  2. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878

  3. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study

    Blood, Vol. 120, Núm. 8, pp. 1589-1596

2011

  1. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

    Blood, Vol. 118, Núm. 17, pp. 4547-4553

2008

  1. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy

    Journal of Clinical Oncology, Vol. 26, Núm. 16, pp. 2737-2744

2006

  1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study

    Blood, Vol. 108, Núm. 7, pp. 2165-2172

2005

  1. Genetic abnormalities and patterns of antigenic expression in multiple myeloma

    Clinical Cancer Research, Vol. 11, Núm. 10, pp. 3661-3667

2001

  1. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline-based protocol. A report from the spanish group PETHEMA

    Haematologica, Vol. 86, Núm. 8, pp. 807-813

  2. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

    Blood, Vol. 98, Núm. 6, pp. 1746-1751